Avalo Therapeutics, Inc.
AVTX
$4.78
-$0.10-2.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 441.00K | 820.00K | 807.00K | 1.45M | 1.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 441.00K | 820.00K | 807.00K | 1.45M | 1.93M |
| Cost of Revenue | 15.28M | 10.16M | 3.91M | 5.35M | 9.95M |
| Gross Profit | -14.84M | -9.34M | -3.10M | -3.90M | -8.02M |
| SG&A Expenses | 17.24M | 14.68M | 12.89M | 10.79M | 10.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.31M | 32.13M | 23.01M | 21.33M | 25.37M |
| Operating Income | -40.87M | -31.31M | -22.20M | -19.88M | -23.44M |
| Income Before Tax | -35.02M | -7.97M | -36.21M | -142.87M | -31.53M |
| Income Tax Expenses | 114.00K | -9.00K | 13.00K | 13.00K | 14.00K |
| Earnings from Continuing Operations | -35.13 | -7.96 | -36.22 | -142.88 | -31.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.13M | -7.96M | -36.22M | -142.88M | -31.54M |
| EBIT | -40.87M | -31.31M | -22.20M | -19.88M | -23.44M |
| EBITDA | -40.70M | -31.17M | -22.05M | -19.72M | -23.29M |
| EPS Basic | -33.15 | -39.83 | -67.65 | -209.31 | -381.49 |
| Normalized Basic EPS | -65.10 | -66.25 | -85.59 | -176.11 | -235.21 |
| EPS Diluted | -41.76 | -58.56 | -82.55 | -219.42 | -391.60 |
| Normalized Diluted EPS | -66.36 | -67.51 | -85.59 | -176.11 | -235.21 |
| Average Basic Shares Outstanding | 40.02M | 30.60M | 25.25M | 1.92M | 1.11M |
| Average Diluted Shares Outstanding | 45.26M | 35.84M | 25.25M | 1.92M | 1.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |